Exencial Wealth Advisors LLC Reduces Stock Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Exencial Wealth Advisors LLC decreased its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 2.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 184,794 shares of the company's stock after selling 4,137 shares during the period. Exencial Wealth Advisors LLC's holdings in GE HealthCare Technologies were worth $14,447,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in GEHC. LGT Financial Advisors LLC raised its holdings in shares of GE HealthCare Technologies by 1,673.3% during the third quarter. LGT Financial Advisors LLC now owns 266 shares of the company's stock valued at $25,000 after acquiring an additional 251 shares during the last quarter. Capital Performance Advisors LLP purchased a new stake in shares of GE HealthCare Technologies during the third quarter worth approximately $26,000. Ashton Thomas Securities LLC acquired a new position in GE HealthCare Technologies in the 3rd quarter valued at $26,000. Darwin Wealth Management LLC purchased a new position in GE HealthCare Technologies in the 3rd quarter valued at $31,000. Finally, Continuum Advisory LLC boosted its stake in GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company's stock worth $31,000 after purchasing an additional 168 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GEHC shares. Citigroup raised their price target on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Wells Fargo & Company increased their price objective on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an "overweight" rating in a report on Friday, February 14th. Finally, Jefferies Financial Group upgraded GE HealthCare Technologies from a "hold" rating to a "buy" rating and upped their price target for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, GE HealthCare Technologies presently has a consensus rating of "Moderate Buy" and an average target price of $97.67.

Remove Ads

GE HealthCare Technologies Trading Up 1.4 %

NASDAQ:GEHC traded up $1.17 on Friday, reaching $86.58. 4,075,712 shares of the company's stock were exchanged, compared to its average volume of 2,984,066. The business has a fifty day moving average of $86.63 and a 200-day moving average of $86.13. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 52-week low of $74.51 and a 52-week high of $94.80. The firm has a market capitalization of $39.59 billion, a price-to-earnings ratio of 20.00, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.26 by $0.19. The company had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. As a group, analysts expect that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.